Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Cangene | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Cangene

Revenues up 46% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cangene
 
3Q Revenues: $40.2 million (+46%)

3Q Earnings: $3.8 million (loss of $4.6 million 3Q13)

YTD Revenues: $102.6 million (+24%)

YTD Earnings: $5.0 million (loss of $12.9 million YTD12)

Comments: The increase included an $18.6-million holdback payment from the U.S. government that was triggered by Cangene achieving licensure of botulism antitoxin (BAT). The revenue increase was partially offset by lower HepaGam B sales in the U.S. Also, the prior-year quarter included product and plasma deliveries under the BAT contract and $1.8 million in revenue from non-specialty plasma sales (following the sale of its plasma centers in October 2012, Cangene no longer collects and sells non-specialty plasma). In the third quarter, combined WinRho SDF revenues were flat.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters